NewLink Genetics (NLNK) Reaches $8.51 After 7.00% Down Move; Boston Scientific (BSX) Covered By 22 Bulls

November 14, 2017 - By Michael Collier

Among 28 analysts covering Boston Scientific Corporation (NYSE:BSX), 22 have Buy rating, 0 Sell and 6 Hold. Therefore 79% are positive. Boston Scientific Corporation had 70 analyst reports since July 27, 2015 according to SRatingsIntel. Benchmark maintained it with “Buy” rating and $20 target in Thursday, July 23 report. The firm has “Buy” rating given on Thursday, June 9 by Guggenheim. BMO Capital Markets maintained Boston Scientific Corporation (NYSE:BSX) rating on Thursday, August 31. BMO Capital Markets has “Buy” rating and $30.0 target. The stock of Boston Scientific Corporation (NYSE:BSX) has “Buy” rating given on Friday, February 3 by Needham. Needham maintained Boston Scientific Corporation (NYSE:BSX) on Friday, July 29 with “Buy” rating. As per Monday, September 28, the company rating was upgraded by Needham. UBS initiated Boston Scientific Corporation (NYSE:BSX) on Tuesday, September 22 with “Buy” rating. As per Thursday, March 17, the company rating was initiated by Nomura. The stock of Boston Scientific Corporation (NYSE:BSX) has “Buy” rating given on Tuesday, August 1 by Stifel Nicolaus. The firm has “Neutral” rating given on Friday, July 29 by Wedbush. See Boston Scientific Corporation (NYSE:BSX) latest ratings:

05/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $31.0 Maintain
03/11/2017 Broker: Needham Rating: Buy New Target: $32.0 Maintain
31/10/2017 Broker: SunTrust Rating: Buy New Target: $34.0 Maintain
27/10/2017 Broker: BMO Capital Markets Rating: Outperform Old Target: $30 New Target: $32 Maintain
26/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $32.0 Maintain
26/10/2017 Broker: Needham Rating: Buy New Target: $32.0 Maintain
24/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $36 Initiates Coverage On
11/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $30.0 Maintain
06/10/2017 Broker: Jefferies Rating: Hold New Target: $28.0 Maintain
02/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $31.0 Maintain

The stock of NewLink Genetics Corp (NASDAQ:NLNK) is a huge mover today! About 237,923 shares traded. NewLink Genetics Corp (NASDAQ:NLNK) has risen 49.90% since November 14, 2016 and is uptrending. It has outperformed by 33.20% the S&P500.The move comes after 8 months negative chart setup for the $308.25 million company. It was reported on Nov, 14 by Barchart.com. We have $7.91 PT which if reached, will make NASDAQ:NLNK worth $21.58M less.

Investors sentiment decreased to 0.94 in Q2 2017. Its down 0.19, from 1.13 in 2017Q1. It is negative, as 23 investors sold NewLink Genetics Corp shares while 29 reduced holdings. 17 funds opened positions while 32 raised stakes. 15.81 million shares or 10.39% more from 14.32 million shares in 2017Q1 were reported. New York-based Art Advsr Ltd Liability Corporation has invested 0.01% in NewLink Genetics Corp (NASDAQ:NLNK). Sabby Mngmt Limited Company owns 138,052 shares. Deutsche Bancshares Ag invested in 291,809 shares. Ameritas Invest Prns Inc owns 0% invested in NewLink Genetics Corp (NASDAQ:NLNK) for 1,605 shares. North Star Invest Mngmt has invested 0% of its portfolio in NewLink Genetics Corp (NASDAQ:NLNK). Rhumbline Advisers holds 0% or 24,951 shares. Trexquant Inv L P reported 18,132 shares stake. Renaissance Techs Limited Liability Corp reported 0% in NewLink Genetics Corp (NASDAQ:NLNK). Alpine Woods Capital Lc stated it has 29,200 shares or 0.01% of all its holdings. Price T Rowe Associate Md invested 0% in NewLink Genetics Corp (NASDAQ:NLNK). Wells Fargo Mn has 165,791 shares. Endurant Capital L P reported 84,598 shares. Moreover, Credit Suisse Ag has 0% invested in NewLink Genetics Corp (NASDAQ:NLNK). Bnp Paribas Arbitrage Sa holds 2,251 shares. Ameriprise Financial holds 0% or 101,567 shares in its portfolio.

Among 6 analysts covering NewLink Genetics (NASDAQ:NLNK), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. NewLink Genetics had 15 analyst reports since March 23, 2016 according to SRatingsIntel. Robert W. Baird maintained the stock with “Buy” rating in Friday, October 13 report. The company was upgraded on Friday, September 8 by Jefferies. Jefferies maintained NewLink Genetics Corp (NASDAQ:NLNK) on Thursday, June 8 with “Hold” rating. The firm has “Buy” rating given on Thursday, August 31 by Stifel Nicolaus. Cantor Fitzgerald maintained NewLink Genetics Corp (NASDAQ:NLNK) rating on Sunday, June 4. Cantor Fitzgerald has “Buy” rating and $3200 target. Robert W. Baird initiated it with “Outperform” rating and $27 target in Wednesday, March 23 report. The rating was maintained by Jefferies on Thursday, August 24 with “Hold”. Stifel Nicolaus maintained the shares of NLNK in report on Monday, July 10 with “Buy” rating. Jefferies maintained NewLink Genetics Corp (NASDAQ:NLNK) rating on Friday, November 3. Jefferies has “Buy” rating and $25 target. The company was upgraded on Thursday, March 30 by SunTrust.

NewLink Genetics Corporation is a clinical-stage immuno-oncology firm focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The company has market cap of $308.25 million. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. It currently has negative earnings. The Company’s biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells.

Analysts await NewLink Genetics Corp (NASDAQ:NLNK) to report earnings on February, 27. They expect $-0.69 earnings per share, down 50.00% or $0.23 from last year’s $-0.46 per share. After $-0.69 actual earnings per share reported by NewLink Genetics Corp for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Since May 17, 2017, it had 0 buys, and 4 insider sales for $1.16 million activity. $82,313 worth of Boston Scientific Corporation (NYSE:BSX) was sold by Pierce David A on Thursday, June 1. Pratt Timothy A. had sold 10,000 shares worth $271,261 on Thursday, June 1. Another trade for 28,864 shares valued at $754,454 was sold by Ballinger Kevin J.. The insider Phalen Michael P. sold $422,369.

About 1.67 million shares traded. Boston Scientific Corporation (NYSE:BSX) has risen 19.12% since November 14, 2016 and is uptrending. It has outperformed by 2.42% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com